NLS Pharmaceutics
NLSP
Market cap $12.4M

3.26 USD

+0.00

0.00%

At close Nov 18, 4:00 PM EST

Pre-market

3.26

+0.00

0.00%

1 day

0.00%

5 days

3.49%

1 month

-31.51%

3 months

-54.02%

6 months

-53.95%

Year to date

-86.14%

1 year

-81.52%

5 years

-97.18%

10 years

-97.18%

About: NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.

Employees: 250

0

Funds holding %

of 6,735 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

6.97% less ownership

Funds ownership: 19.65% [Q2] → 12.68% (-6.97%) [Q3]

59% less capital invested

Capital invested by funds: $1.85M [Q2] → $752K (-$1.1M) [Q3]

80% less funds holding

Funds holding: 10 [Q2] → 2 (-8) [Q3]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 8

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for NLSP.

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about NLSP published over the past 30 days

NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders

ZÜRICH, SWITZERLAND / ACCESSWIRE / November 18, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, provided insights today into the preclinical program evaluating its dual orexin receptor agonist (DOXA) platform.

NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement

ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL / ACCESSWIRE / November 4, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS"), a biopharmaceutical company, and Kadimastem Ltd.

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement

NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements

ZURICH, SWITZERLAND / ACCESSWIRE / October 28, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it has received notice from the Nasdaq Stock Market LLC ("NASDAQ") informing the Company that it has regained full compliance with the bid price requirement in Listing Rule 5550(a)(2) and the equity requirement in Listing Rule 5550(b)(1).

NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements

NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence

ZURICH, SWITZERLAND / ACCESSWIRE / October 21, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to developing therapies for rare and complex central nervous system disorders, is pleased to announce that its Japanese patent application No.

NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence

NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules

ZURICH, SWITZERLAND / ACCESSWIRE / October 15, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced the closing of a private placement offering consisting of the issuance and sale of 806,452 common shares, par value CHF 0.80 per share and common share purchase warrants to purchase 806,452 common shares, at a combined purchase price of $3.97, for aggregate gross proceeds of $3.2 million.

NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules

NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split

ZURICH, SWITZERLAND / ACCESSWIRE / September 25, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that a reverse share split of the Company's issued and outstanding common shares, par value CHF 0.02 per share (the "Common Shares"), at a ratio of 1-for-40 is expected to be implemented at market open on September 27, 2024 (the "Reverse Split").

NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split

Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining around 0.4% on Monday.

Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump

Why Is NLS Pharmaceutics (NLSP) Stock Up 48% Today?

NLS Pharmaceutics (NASDAQ: NLSP ) stock is on the rise Monday after the clinical-stage biopharmaceutical company announced a merger agreement with Kadimastem. This agreement will see Kadimastem acquired by a wholly-owned subsidiary of NLS Pharmaceutics.

Why Is NLS Pharmaceutics (NLSP) Stock Up 48% Today?

NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge

The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused on advancing Kadimastem's allogeneic cell therapy platform Each of Kadimastem and NLS Pharmaceutics has received commitments of support for the transaction from shareholders representing more than 40% of their respective outstanding shares ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL / ACCESSWIRE / July 29, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS"), a biopharmaceutical company.

NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge

NLS Pharmaceutics Announces Registered Direct Offering

ZURICH, SWITZERLAND / ACCESSWIRE / June 28, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,277,750 of its common shares at a purchase price of $0.24 per share in a registered direct offering.

NLS Pharmaceutics Announces Registered Direct Offering

See News Rankings

Charts implemented using Lightweight Charts™